RANDOMIZED, OPEN-LABEL PHASE 3B STUDY OF ETROLIZUMAB BASED INDUCTION THERAPY COMBINATIONS FOLLOWED BY ETROLIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Etrolizumab (Primary) ; Infliximab (Primary) ; Tofacitinib (Primary) ; Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms Lantana
- Sponsors Roche
Most Recent Events
- 30 Sep 2024 Status changed from recruiting to completed.
- 15 Sep 2020 New trial record